Candidates for antenatal IVIG therapy are typically identified through prenatal screening and diagnostic tests. Women who have had a previous pregnancy affected by alloimmune thrombocytopenia or HDFN are prime candidates. Additionally, those with serological evidence of infections like CMV or parvovirus B19, which pose a risk to the fetus, may also be considered for this therapy.
